Skip to content
Cambridge, MA
18°
Partly Cloudy
7:05 am
4:46 pm EST
Feels like: 7
°F
Wind: 11
mph
W
Humidity: 45
%
Pressure: 30.51
"Hg
UV index: 1
11:29am
⚲
About
About KSA
About Kendall Square
Membership
About Membership
Member Directory
Member Map
Events + Programs
At the KSA
Kendall Calendar
Policy + Advocacy
Policy + Advocacy
Government Relations
Kendall GREEN: Sustainability
Transportation
Workforce Development
News + Stories
News + Stories
Blogs
In The News
Newsletters
Social Media
Resources
Resources
Cater Kendall
Innovation Trail
Kendall Calendar
Kendall Square Construction Projects
Kendall Volunteers
About
About KSA
About Kendall Square
Membership
About Membership
Member Directory
Member Map
Events + Programs
At the KSA
Kendall Calendar
Policy + Advocacy
Policy + Advocacy
Government Relations
Kendall GREEN: Sustainability
Transportation
Workforce Development
News + Stories
News + Stories
Blogs
In The News
Newsletters
Social Media
Resources
Resources
Cater Kendall
Innovation Trail
Kendall Calendar
Kendall Square Construction Projects
Kendall Volunteers
Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug, zuranolone.
Dec 01, 2020
Share
Share on Twitter
Share on Facebook
Close
Previous
←
Next
→
/